AIF4- inhibits influx of Ca2+ into vascular smooth muscle cells.
Hughes
A D
AD
Department of Clinical Pharmacology, St. Mary's Hospital Medical School, ICSTM, London, UK.
Schachter
M
M
D017607:Aluminum Compounds / Q000494:pharmacology*; D000818:Animals; D001013:Aorta, Thoracic; D002118:Calcium / Q000378:metabolism*; D002460:Cell Line; D004533:Egtazic Acid / Q000494:pharmacology; D004622:Embryo, Mammalian; D005459:Fluorides / Q000494:pharmacology*; D019204:GTP-Binding Proteins / Q000502:physiology; D015759:Ionomycin / Q000494:pharmacology; D007700:Kinetics; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D015398:Signal Transduction; D014667:Vasopressins / Q000494:pharmacology
D017607:Aluminum Compounds; D014667:Vasopressins; C050992:tetrafluoroaluminate; D004533:Egtazic Acid; D015759:Ionomycin; D019204:GTP-Binding Proteins; D005459:Fluorides; D002118:Calcium